$92,501,232

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

biotechactiveONGOING · MOD OF 2024 CONTRACT

WORK BEGAN2024-09-30·LATEST ACTION2026-04-24·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50124C00033_7505_-NONE-_-NONE-

Award description

THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Development of new antimicrobial drugs to treat resistant fungal and bacterial infections under an ongoing contract that began in September 2024.

Sub-sectors

antimicrobial-developmentfungal-bacterial-resistancepharma-r&d

Why this matters

Antimicrobial resistance is a critical public health threat; this 7-year program funds novel therapeutics to address drug-resistant pathogens.

Supply-chain signal

Success depends on Basilea's manufacturing scale-up and regulatory pathway; downstream demand from hospitals and clinics for approved treatments.

U.S.–China competition angle

China is expanding biotech and pharma capacity; U.S. investment in novel antimicrobials reduces dependence on foreign drug supply chains.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-30. Cost: $0.003064.

Period of performance

Start

2024-09-30

End

2031-09-30

Status

activein 1918 days

Recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50124C00033_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.